Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Abstract

AbstractFollowing publication of the original article [1], the authors notified us of some misreported data due to the publication of the EVOLVE-2 trial (Cephalalgia. 2018;38:1442-1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine. All changes are marked in bold and with red in Figure 1 and Figure 2. Please note that the final recommendations remain unchanged.

Figures

Fig. 1

Process of identifying eligible studies for the guideline. The number of included studies has been modified from 28 to 29

Fig. 2

Risk of bias summary for the studies considered for the guideline. The EVOLVE 2 line was replaced wi Skljarevski, 2018. A new line was introduced for EVOLVE 2 (linked to reference 51) right under Sun, 2016